The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study

Breast Cancer Clinical Trial

Official title:

The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06220630
• Other study ID #: 2021[516]
• Status: Recruiting
• Start date: August 1, 2021
• Est. completion date: December 31, 2025

Study information

• Verified date: January 2024
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: Yuxuan Gao, MD
• Phone: +86 18142846375
• Email: gaoyx9[@]mail2.sysu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: - The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population.

Description:

The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: - The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population. The collected variables included: survival time, survival status, year of diagnosis, age, stage, molecular subtype statuses, histology, grade, and surgery, radiotherapy and systemic therapies utilization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: December 31, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Biological sex is male;
• Microscopically diagnosed as primary breast cancer.

Exclusion Criteria:

• Presence of skin-origin malignancy on the breast.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Breast Neoplasms, Male

Intervention

Other:
• Breast cancer
Male patients who were microscopically diagnosed as primary breast cancer.

Locations

Country	Name	City	State
China	First affiliated hospital of Sun Yat-sen university	Guangzhou	Guangdong

Sponsors (33)

Lead Sponsor

Collaborator

First Affiliated Hospital, Sun Yat-Sen University

Affiliated Sanming First Hospital of Fujian Medical University, Beijing 302 Hospital, Beijing Medical Award Foundation, First Affiliated Hospital Xi'an Jiaotong University, First Hospital of China Medical University, First People's Hospital of Foshan, Fujian Provincial Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Guangdong Women and Children Hospital, Jiangmen Central Hospital, Jieyang People's Hospital, Lianjiang Pepole's Hospital, Lianjiang, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Peking University First Hospital, Peking University Shenzhen Hospital, Shantou Central Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, The Affiliated Cancer Hospital of Xinjiang Medical University, The Affiliated Cancer Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital, Zhejiang University, The Fourth Hospital of Hebei Medical University, The Second Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital, Guangzhou Medical University, The Third Affiliated Hospital of Kunming Medical University, The Third Hospital of Nanchang City, Zhanjiang Central Hospital, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The duration between the date of the first pathologic diagnosis and death from any cause or last follow-up.	From the time of diagnosis to August 1, 2024 (anticipated).